Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.31 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18482731 | 0.93 | SLC34A2 (0.39) | SLC34A2TP53BP1EPHX2 | |
| SCHEMBL10274107 | 0.92 | SLC34A2 (0.34) | SLC34A2TP53BP1EPHX2 | |
| SCHEMBL15432827 | 0.90 | TAOK1 (0.34) | SLC34A2TLR2TLR1 | |
| SCHEMBL15444471 | 0.90 | TAOK1 (0.34) | SLC34A2TLR2TLR1 | |
| SCHEMBL47722 | 0.88 | SLC34A2 (0.39) | SLC34A2TP53BP1EPHX2 | |
| SCHEMBL19596089 | 0.86 | SLC34A2 (0.37) | SLC34A2 | |
| SCHEMBL18482346 | 0.85 | SLC34A2 (0.38) | SLC34A2TP53BP1EPHX2 | |
| SCHEMBL10274263 | 0.84 | IRAK4 (0.33) | SLC34A2TP53BP1EPHX2 | |
| SCHEMBL39973 | 0.83 | CTSS (0.34) | SLC34A2 | |
| SCHEMBL15432830 | 0.83 | CTSS (0.34) | SLC34A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | SLC34A2 1/4885TLR2 4817/4885TLR1 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.